The peanut oral immunotherapy trial, POSEIDON, revealed promising outcomes in desensitizing preschool children with a peanut allergy, potentially reshaping early intervention strategies.
A phase 1 randomized, controlled trial tested the safety of a toothpaste that was specially formulated to be used as oral immunotherapy by adults with peanut allergy.